IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 294 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $430,421 | +11.3% | 9,489 | +0.7% | 0.00% | – |
Q2 2023 | $386,749 | -76.3% | 9,426 | -79.4% | 0.00% | -100.0% |
Q1 2023 | $1,634,246 | -35.1% | 45,726 | -31.4% | 0.00% | 0.0% |
Q4 2022 | $2,516,426 | -13.0% | 66,625 | +1.8% | 0.00% | -50.0% |
Q3 2022 | $2,894,000 | +140.6% | 65,426 | +101.5% | 0.00% | +100.0% |
Q2 2022 | $1,203,000 | -2.7% | 32,465 | -2.7% | 0.00% | 0.0% |
Q1 2022 | $1,236,000 | +188.8% | 33,362 | +136.8% | 0.00% | – |
Q4 2021 | $428,000 | -75.0% | 14,087 | -72.3% | 0.00% | -100.0% |
Q3 2021 | $1,709,000 | -81.7% | 50,946 | -78.3% | 0.00% | -80.0% |
Q2 2021 | $9,350,000 | +29.5% | 234,386 | +46.0% | 0.01% | +25.0% |
Q1 2021 | $7,218,000 | -18.1% | 160,567 | +3.0% | 0.00% | -20.0% |
Q4 2020 | $8,810,000 | -28.5% | 155,823 | -40.0% | 0.01% | -37.5% |
Q3 2020 | $12,320,000 | +16.4% | 259,617 | +44.6% | 0.01% | 0.0% |
Q2 2020 | $10,585,000 | +51.2% | 179,545 | +21.2% | 0.01% | +33.3% |
Q1 2020 | $7,002,000 | -65.6% | 148,130 | -56.0% | 0.01% | -53.8% |
Q4 2019 | $20,330,000 | +72.2% | 336,582 | +70.8% | 0.01% | +62.5% |
Q3 2019 | $11,803,000 | -80.3% | 197,069 | -78.9% | 0.01% | -77.1% |
Q2 2019 | $59,942,000 | +619.2% | 932,733 | +808.0% | 0.04% | +600.0% |
Q1 2019 | $8,335,000 | +180.5% | 102,719 | +86.8% | 0.01% | +150.0% |
Q4 2018 | $2,971,000 | -74.4% | 54,997 | -75.5% | 0.00% | -33.3% |
Q3 2018 | $11,584,000 | -36.9% | 224,628 | -49.0% | 0.00% | -40.0% |
Q2 2018 | $18,355,000 | +16.8% | 440,582 | +23.6% | 0.01% | -28.6% |
Q1 2018 | $15,714,000 | +81.6% | 356,560 | +107.2% | 0.01% | +16.7% |
Q4 2017 | $8,653,000 | -87.3% | 172,113 | -87.2% | 0.01% | -87.2% |
Q3 2017 | $68,022,000 | +179.2% | 1,341,733 | +180.1% | 0.05% | +176.5% |
Q2 2017 | $24,360,000 | +14.0% | 478,939 | -10.0% | 0.02% | +6.2% |
Q1 2017 | $21,376,000 | -37.1% | 531,872 | -25.2% | 0.02% | -40.7% |
Q4 2016 | $33,986,000 | +17.8% | 710,620 | -9.8% | 0.03% | +35.0% |
Q3 2016 | $28,851,000 | +11.7% | 787,515 | -29.0% | 0.02% | +11.1% |
Q2 2016 | $25,833,000 | -15.9% | 1,109,350 | +46.2% | 0.02% | -21.7% |
Q1 2016 | $30,721,000 | -28.8% | 758,626 | +8.9% | 0.02% | -23.3% |
Q4 2015 | $43,142,000 | – | 696,674 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |